These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 6635123)

  • 1. Oral physostigmine in Alzheimer's disease.
    Davis KL; Mohs RC; Davis BM; Horvath TB; Greenwald BS; Rosen WG; Levy MI; Johns CA
    Psychopharmacol Bull; 1983; 19(3):451-3. PubMed ID: 6635123
    [No Abstract]   [Full Text] [Related]  

  • 2. Memory enhancement with oral physostigmine in Alzheimer's disease.
    N Engl J Med; 1983 Mar; 308(12):720-1. PubMed ID: 6338388
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term administration of oral physostigmine and lecithin improve memory in Alzheimer's disease.
    Levin HS; Peters BH
    Ann Neurol; 1984 Feb; 15(2):210. PubMed ID: 6703661
    [No Abstract]   [Full Text] [Related]  

  • 4. Lack of clinical efficacy of chronic oral physostigmine in Alzheimer's disease.
    Jotkowitz S
    Ann Neurol; 1983 Dec; 14(6):690-1. PubMed ID: 6360031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma.
    Peskind ER; Wingerson D; Pascualy M; Thal L; Veith RC; Dorsa DM; Bodenheimer S; Raskind MA
    Biol Psychiatry; 1995 Oct; 38(8):532-8. PubMed ID: 8562665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertension associated with oral administration of physostigmine in a patient with Alzheimer's disease.
    Cain JW
    Am J Psychiatry; 1986 Jul; 143(7):910-2. PubMed ID: 3717434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral physostigmine and lecithin improve memory in Alzheimer's disease.
    Thal LJ; Fuld PA; Masur DM; Sharpless NS; Davies P
    Psychopharmacol Bull; 1983; 19(3):454-6. PubMed ID: 6635124
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine.
    Asthana S; Raffaele KC; Berardi A; Greig NH; Haxby JV; Schapiro MB; Soncrant TT
    Alzheimer Dis Assoc Disord; 1995; 9(4):223-32. PubMed ID: 8749612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial.
    Jenike MA; Albert M; Baer L; Gunther J
    J Geriatr Psychiatry Neurol; 1990; 3(1):13-6. PubMed ID: 2189429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.
    Asthana S; Greig NH; Hegedus L; Holloway HH; Raffaele KC; Schapiro MB; Soncrant TT
    Clin Pharmacol Ther; 1995 Sep; 58(3):299-309. PubMed ID: 7554703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral physostigmine treatment of patients with Alzheimer's disease.
    Mohs RC; Davis BM; Johns CA; Mathé AA; Greenwald BS; Horvath TB; Davis KL
    Am J Psychiatry; 1985 Jan; 142(1):28-33. PubMed ID: 3881051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term administration of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Neurology; 1988 Dec; 38(12):1837-41. PubMed ID: 3057398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
    Wettstein A
    Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease.
    Thal LJ; Masur DM; Blau AD; Fuld PA; Klauber MR
    J Am Geriatr Soc; 1989 Jan; 37(1):42-8. PubMed ID: 2642499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl.
    Sunderland T; Molchan S; Lawlor B; Martinez R; Mellow A; Martinson H; Putnam K; Lalonde F
    Int Psychogeriatr; 1992; 4 Suppl 2():291-309. PubMed ID: 1288668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies.
    Mohs RC; Davis BM; Greenwald BS; Mathé AA; Johns CA; Horvath TB; Davis KL
    J Am Geriatr Soc; 1985 Nov; 33(11):749-57. PubMed ID: 2865282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
    Canal N; Imbimbo BP
    Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of long-term physostigmine administration in Alzheimer's disease.
    Harrell LE; Callaway R; Morere D; Falgout J
    Neurology; 1990 Sep; 40(9):1350-4. PubMed ID: 2392216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral physostigmine as treatment for dementia of the Alzheimer type: a long-term outpatient trial.
    Jenike MA; Albert MS; Baer L
    Alzheimer Dis Assoc Disord; 1990; 4(4):226-31. PubMed ID: 2264980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease.
    Sano M; Bell K; Marder K; Stricks L; Stern Y; Mayeux R
    Clin Neuropharmacol; 1993 Feb; 16(1):61-9. PubMed ID: 8422658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.